Multispectral and phase-contrast diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study

2009 ◽  
Author(s):  
Xiaoping Liang ◽  
Qizhi Zhang ◽  
Stephen Staal ◽  
Stephen Grobmyer ◽  
Huabei Jiang
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Phase Contrast ◽  
Optical Tomography ◽  
Diffuse Optical Tomography

Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: A case study with comparison to MRI

2005 ◽  
Vol 32 (4) ◽  
pp. 1128-1139 ◽  
Author(s):  
Regine Choe ◽  
Alper Corlu ◽  
Kijoon Lee ◽  
Turgut Durduran ◽  
Soren D. Konecky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Optical Tomography ◽  
Diffuse Optical Tomography

scholarly journals Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Mirella L. Altoe ◽  
Kevin Kalinsky ◽  
Alessandro Marone ◽  
Hyun K. Kim ◽  
Hua Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Optical Tomography ◽  
Pathologic Complete Response ◽  
Negative Relationship ◽  
Diffuse Optical Tomography ◽  
Complete Response ◽  
Normal Breast ◽  
Mixed Effect ◽  
Tumor Bearing

Abstract Background The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR). Methods In this retrospective evaluation of 105 patients with stage II–III breast cancer, oxy-hemoglobin (ctO2Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2–3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO2Hb changes across chemotherapy when corrected for pCR status, age, and BMI. Results Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO2Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2–3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, − 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO2Hb levels with BMI and age. Conclusions This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2–3 weeks of chemotherapy.

Breast cancer detection using phase contrast diffuse optical tomography

2007 ◽  
Author(s):  
Xiaoping Liang ◽  
Qizhi Zhang ◽  
Changqing Li ◽  
Stephen R. Grobmyer ◽  
Laurie L. Fajardo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Detection ◽  
Phase Contrast ◽  
Optical Tomography ◽  
Diffuse Optical Tomography ◽  
Breast Cancer Detection

scholarly journals Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy

2019 ◽  
Vol 10 (8) ◽  
pp. 4305
Author(s):  
Mirella L. Altoe ◽  
Alessandro Marone ◽  
Hyun K. Kim ◽  
Kevin Kalinsky ◽  
Dawn L. Hershman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Risk ◽  
Optical Tomography ◽  
Diffuse Optical Tomography
Sign in / Sign up

Export Citation Format

Share Document